Gulf Pharmaceutical Industries (Julphar) has announced a strong start to 2026, recording a revenue of Dh573.7 million for the first half of the year. This represents a steady 4.7% increase compared to the same period in 2025. Despite broader economic headwinds, such as global supply chain disruptions and rising inflationary costs, the company successfully boosted its gross profit by 18.3% to reach Dh261.2 million. The firm’s EBITDA saw a significant surge of 84.7%, climbing to Dh86.8 million, while net income from continuing operations rose sharply to Dh56.2 million, highlighting the effectiveness of its focus on operational efficiency and a more profitable product mix.

Beyond these financial gains, Julphar has made notable strides in strengthening its market presence and balance sheet. The company successfully reduced its accumulated losses by Dh56.1 million and ended the half-year with equity reaching Dh1.016 billion, providing a solid foundation for future investments. On the operational front, the company launched four new products in the UAE and secured sixteen international registrations, further cementing its reach in key regions like Saudi Arabia. According to company leadership, these results validate their ongoing strategy of disciplined execution and operational excellence, ensuring the business is well-positioned for sustainable long-term growth and enhanced shareholder value.